Comparing PSMA PETCT and MRI-RSI Imaging to Detect and Outline Tumors in Men with Newly Diagnosed Primary Prostate Cancer

What this Trial Is About

Researchers are comparing two advanced imaging techniques, MRI-RSI and PSMA PETCT, with the current standard multiparametric MRI mpMRI to improve the detection and outlining of tumors inside the prostate in men newly diagnosed with primary prostate cancer. This study focuses on men with intermediate to very high-risk prostate cancer to assess how these imaging methods may better identify the tumor burden and reduce variability between observers. The goal is to enhance personalized treatment planning for prostate cancer patients. Participants will undergo MRI-RSI imaging, PSMA PETCT scans, and MR-guided transrectal ultrasound TRUS prostate biopsies following standard protocols. The study will prospectively compare these imaging methods to evaluate their effectiveness in detecting and outlining tumors. These tests are non-invasive or minimally invasive diagnostic procedures conducted before any systemic therapy. During the 24-month study period, researchers will measure how well each imaging method detects tumors, including sensitivity, specificity, and tumor volume measurements. They will also assess the agreement between observers and the relationship between imaging results and radiation dose planning. Participants will be monitored throughout the study to collect imaging data and biopsy results, supporting a thorough evaluation of each techniques usefulness in prostate cancer care.

Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer